J&J, Roche lead January's journal-ad numbers; Novartis nabs new approval for Jakavi; Aussie watchdog to appeal Pfizer ruling;

> Johnson & Johnson ($JNJ) spent more than $2.5 million on medical journal advertising in January, putting itself in line to lead pharma's journal-ad pack as it did in 2014; Roche's ($RHHBY) January numbers came in second at $1.5 million. Release

> Novartis ($NVS) won European approval for Jakavi, its JAK inhibitor, to treat adults with polycythemia vera, a rare and incurable blood cancer. Release

> Pfizer's ($PFE) court fight over Lipitor discounting in Australia isn't over yet; the country's consumer watchdog says it will appeal a federal judge's decision that the company hadn't engaged in anticompetitive conduct. Report

> Boehringer Ingelheim is poised to roll out its idiopathic pulmonary fibrosis drug Ofev in Europe, with an on-sale date in Germany this week. Report

> Teva Pharmaceutical Industries ($TEVA) beefed up its oncology pipeline with a deal to buy four of Ignyta's drug candidates and invest in the biotech drug developer. Release

And Finally... A Novo Nordisk ($NVO) documentary about Type 2 diabetes in Ghana is up for a vote in the annual Boston College Center for Corporate Citizenship Film Festival. Report

Suggested Articles

Novartis said it plans to use the complete response rate data for a U.S. filing in follicular lymphoma in 2021.

Amarin's wild 2020 ride continues with plans to launch its cardiovascular med Vascepa in Europe without a bigger marketing partner.

The CD19 antibody, used in tandem with Celgene's Revlimid, represents the first FDA approval in second-line diffuse large B-cell lymphoma.